> top > docs > PubMed:23994795 > annotations

PubMed:23994795 JSONTXT

Annnotations TAB JSON ListView MergeView

Allie

Id Subject Object Predicate Lexical cue
SS1_23994795_1_0 31-59 expanded denotes Systemic lupus erythematosus
SS2_23994795_1_0 61-64 abbr denotes SLE
SS1_23994795_4_0 467-478 expanded denotes interferons
SS2_23994795_4_0 480-484 abbr denotes IFNs
AE1_23994795_1_0 SS1_23994795_1_0 SS2_23994795_1_0 abbreviatedTo Systemic lupus erythematosus,SLE
AE1_23994795_4_0 SS1_23994795_4_0 SS2_23994795_4_0 abbreviatedTo interferons,IFNs

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 31-59 HP_0002725 denotes Systemic lupus erythematosus
T2 80-98 HP_0002960 denotes autoimmune disease
T3 80-90 HP_0002960 denotes autoimmune

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-30 Sentence denotes Interferon α-targeted therapy.
T2 31-180 Sentence denotes Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of autoantibodies to various cellular components.
T3 181-277 Sentence denotes Although many of therapies have shown great efficacy, they often associate with adverse effects.
T4 278-436 Sentence denotes The development of safer therapies for SLE has led to recent emphasis on targeting selected pathways that can be important in the inflammatory process in SLE.
T5 437-559 Sentence denotes The cytokine family of type I interferons (IFNs), and especially the IFNα subtypes, are implicated in pathogenesis of SLE.
T6 560-684 Sentence denotes Genetic polymorphisms of several components of the IFN signaling pathway have been associated with an increased risk of SLE.
T7 685-781 Sentence denotes Therefore, IFNα subtypes have been identified as a potential target for drug development in SLE.
T8 782-894 Sentence denotes There have been developed three agents, IFNα-targeted therapy, Sifalimumab, Rontalizumab and NNC 0152-0000-0001.
T9 895-1051 Sentence denotes They are anti-IFNα monoclonal antibodies that bind to and specifically neutralizes most IFNα subtypes, preventing signaling through the type I IFN receptor.
T10 1052-1136 Sentence denotes The safety and dose-proportional pharmacokinetics of those agents were demonstrated.
T11 1137-1215 Sentence denotes A larger study is currently ongoing, further safety profile will be evaluated.
T12 1216-1360 Sentence denotes This review provides an update on the ongoing clinical trials of anti-IFNα therapy and the promise and obstacles in the use of biologics in SLE.
T1 0-30 Sentence denotes Interferon α-targeted therapy.
T2 31-180 Sentence denotes Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of autoantibodies to various cellular components.
T3 181-277 Sentence denotes Although many of therapies have shown great efficacy, they often associate with adverse effects.
T4 278-436 Sentence denotes The development of safer therapies for SLE has led to recent emphasis on targeting selected pathways that can be important in the inflammatory process in SLE.
T5 437-559 Sentence denotes The cytokine family of type I interferons (IFNs), and especially the IFNα subtypes, are implicated in pathogenesis of SLE.
T6 560-684 Sentence denotes Genetic polymorphisms of several components of the IFN signaling pathway have been associated with an increased risk of SLE.
T7 685-781 Sentence denotes Therefore, IFNα subtypes have been identified as a potential target for drug development in SLE.
T8 782-894 Sentence denotes There have been developed three agents, IFNα-targeted therapy, Sifalimumab, Rontalizumab and NNC 0152-0000-0001.
T9 895-1051 Sentence denotes They are anti-IFNα monoclonal antibodies that bind to and specifically neutralizes most IFNα subtypes, preventing signaling through the type I IFN receptor.
T10 1052-1136 Sentence denotes The safety and dose-proportional pharmacokinetics of those agents were demonstrated.
T11 1137-1215 Sentence denotes A larger study is currently ongoing, further safety profile will be evaluated.
T12 1216-1360 Sentence denotes This review provides an update on the ongoing clinical trials of anti-IFNα therapy and the promise and obstacles in the use of biologics in SLE.